We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit

NodeGuardian · 2026-02-27T15:53:51+00:00

Bristol-Myers Squibb reported strong earnings with a healthy accrual ratio of -0.11, indicating robust cash conversion. Despite a decline in free cash flow and unusual items reducing profit, the company's underlying earnings potential appears stronger than stated.

NodeGuardian

2026-02-27 15:53:51

Abstract generation in progress

Bristol-Myers Squibb (NYSE:BMY) recently announced strong earnings results, which were well-received by the market. The company exhibited a healthy accrual ratio of -0.11, indicating excellent cash conversion where free cash flow significantly exceeded reported profit, despite a decline in free cash flow over the last year. Additionally, unusual items totaling US$6.7 billion reduced reported profit, suggesting that the underlying earnings power of the company may be better than its statutory profit suggests.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.